|
US20080305120A1
(en)
|
2004-06-17 |
2008-12-11 |
Medimmune, Inc. |
Immunogenic Compositions Comprising Hmgb 1 Polypeptides
|
|
DE102004034461B4
(de)
|
2004-07-16 |
2008-02-07 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
ES2291071B1
(es)
|
2005-06-13 |
2009-03-16 |
Proyecto De Biomedicina Cima, S.L. |
Agentes y metodos basados en el uso del dominio eda de la fibronectina.
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
CN101970499B
(zh)
|
2008-02-11 |
2014-12-31 |
治疗科技公司 |
用于肿瘤治疗的单克隆抗体
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
EP2323685A2
(en)
|
2008-07-11 |
2011-05-25 |
Medizinische Universität Innsbruck |
Agonists of nr2f6 for immunosuppression
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
DE102008050860A1
(de)
|
2008-10-08 |
2010-04-15 |
Dorothee Von Laer |
LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
EP2476440B1
(en)
|
2009-09-11 |
2017-08-02 |
Proyecto de Biomedicina Cima, S.L. |
Therapeutic compositions for the treatment of hpv-induced diseases
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
|
US8999349B2
(en)
|
2010-07-27 |
2015-04-07 |
The Regents Of The University Of California |
HMGB1-derived peptides enhance immune response to antigens
|
|
WO2012048190A1
(en)
|
2010-10-08 |
2012-04-12 |
Regents Of The University Of Minnesota |
Annexin ii compositions and methods
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
WO2013102144A2
(en)
|
2011-12-30 |
2013-07-04 |
Halozyme, Inc. |
Ph20 polypeptede variants, formulations and uses thereof
|
|
WO2013120073A1
(en)
|
2012-02-09 |
2013-08-15 |
Av Therapeutics, Inc. |
Synthetic toll-like receptor-4 (tlr-4) agonist peptides
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
HUE067838T2
(hu)
*
|
2016-09-21 |
2024-11-28 |
Amal Therapeutics Sa |
Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére
|
|
TWI894135B
(zh)
*
|
2019-01-25 |
2025-08-21 |
德商百靈佳殷格翰國際股份有限公司 |
編碼ccl21之重組棒狀病毒
|